Biogen Sets Aside Cash For Business Development, Expects New Launches In 2014
The spec pharma had a strong year and will continue to rely on new product launches going forward, but hopes to bolster its pipeline with early-stage add-ons.
The spec pharma had a strong year and will continue to rely on new product launches going forward, but hopes to bolster its pipeline with early-stage add-ons.